1.29

4.03% 0.05

After Hours: 1.24 -0.05 -3.88%

Pmv Pharmaceuticals Inc (PMVP)

Overview News Price History Option Chain Financials Discussions Forecast

Pmv Pharmaceuticals Inc stock is traded at $1.29, with a volume of 529.98K. It is up +4.03% in the last 24 hours and up +10.26% over the past month. PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Previous Close:

$1.24

Open:

$1.24

24h Volume:

529.98K

Relative Volume:

1.28

Market Cap:

$68.96M

Revenue:

Net Income/Loss:

$-78.34M

P/E Ratio:

-0.8705

EPS:

-1.4819

Net Cash Flow:

$-75.02M

1W Performance:

+5.74%

1M Performance:

+10.26%

6M Performance:

-14.00%

1Y Performance:

-10.42%

1-Day Range:

$1.24

$1.35

1-Week Range:

$1.115

$1.35

52-Week Range:

$1.02

$1.88

Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile

Name

Pmv Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(609) 642-6670

Address

400 ALEXANDER PARK DRIVE, PRINCETON

Employee

Twitter

Next Earnings Date

2026-08-20

Latest SEC Filings

PMVP's Discussions on Twitter

Compare PMVP vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PMVP Pmv Pharmaceuticals Inc	1.29	69.50M	0	-78.34M	-75.02M	-1.4819
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Upgrade	Oppenheimer	Perform → Outperform
May-13-24	Initiated	Craig Hallum	Buy
Apr-12-24	Initiated	Jefferies	Buy
Dec-27-23	Initiated	Ladenburg Thalmann	Buy
Mar-02-22	Upgrade	Oppenheimer	Perform → Outperform
Sep-22-21	Upgrade	Goldman	Neutral → Buy
Aug-19-21	Initiated	Oppenheimer	Perform
Aug-02-21	Initiated	Guggenheim	Buy
Jul-29-21	Initiated	H.C. Wainwright	Buy
Oct-20-20	Initiated	BofA Securities	Buy
Oct-20-20	Initiated	Cowen	Outperform
Oct-20-20	Initiated	Evercore ISI	Outperform
Oct-20-20	Initiated	Goldman	Neutral

View All

Pmv Pharmaceuticals Inc Stock (PMVP) Latest News

Sep 05, 2026

PMV Pharmaceuticals stock gains as biotech peers advance - AD HOC NEWS

Sep 05, 2026

Sep 04, 2026

Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - Kalkine

Sep 04, 2026

PMV Pharmaceuticals stock gains on HC Wainwright buy rating and 5 dollar target - AD HOC NEWS

Sep 04, 2026

PMVP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus

Sep 04, 2026

Sep 02, 2026

PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering - TipRanks

Sep 02, 2026

Sep 01, 2026

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - Yahoo Finance

Sep 01, 2026

PMV Pharmaceuticals (PMVP) Announces $50.8M Oversubscribed Offering Amid Mixed Market Signals - GuruFocus

Sep 01, 2026

Aug 31, 2026

PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative

Aug 31, 2026

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - GlobeNewswire

Aug 31, 2026

PMV Pharmaceuticals (PMVP) Launches Public Offering Amid Unprofi - GuruFocus

Aug 31, 2026

PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data - TipRanks

Aug 31, 2026

PMV Pharmaceuticals reports 46% ORR in ovarian cohort, plans NDA filing in Q1 2027 - TradingView

Aug 31, 2026

PMV (PMVP) Watch: Moves 1.15% Higher to $1.31; Price Context: Price Remains Between $1.24 Support and $1.38 Resistance in the Latest SessionValue Factor - vinanet.vn

Aug 21, 2026

Aug 19, 2026

PMV (PMVP) Latest Quarter: The Available Earnings Metric Delivers a Beat in the Latest Reading; Closing Move: The Stock Records a 3.23% Increase on the DayAnalyst Coverage Count - vinanet.vn

Aug 19, 2026

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Aug 19, 2026

Aug 14, 2026

PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat

Aug 14, 2026

PMV Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Form 8K Pmv Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Canada

Aug 14, 2026

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times

Aug 14, 2026

PMV Pharma Reports $18.1 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 14, 2026

PMV Pharmaceuticals (PMVP) flags going-concern risk as rezatapopt advances toward NDA - Stock Titan

Aug 14, 2026

PMVP: Net loss narrowed, but liquidity concerns persist as rezatapopt advances toward NDA submission - TradingView

Aug 14, 2026

Press Release: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - Moomoo

Aug 14, 2026

Aug 10, 2026